ArticleMaterials today. Bio2025
Injectable cationic dynamic hydrogel with supramolecular drug loading reprograms neutrophil fate to alleviate diabetic periodontitis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pervasive infiltration of tissue-destructive yet microbicidal-impaired neutrophil extracellular traps (NETs) constitutes a primary mechanistic driver of diabetic periodontitis refractoriness. Apoptosis facilitates nonphlogistic turnover of neutrophils, but excessive activation leads to the release of an excessive amount of dysfunctional NETs, causing tissue damage in diabetic periodontitis. To co-target pathological NETosis and dysbiotic infection, we engineered an injectable cationic dynamic hydrogel (ICDH) with supramolecular drug loading via grafting phenylboronic acid onto cationic poly-L-lysine, crosslinking with polyvinyl alcohol via dynamic borate esters, and loading immunomodulatory agents (chlorogenic acid and metformin) via supramolecular interactions. This innovative design confers robust tissue adhesion, microenvironmental responsivity to pH/glucose/ROS, enabling broad-spectrum antibacterial efficacy against
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.